TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Consensus Price Target from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $9.33.

TCRX has been the subject of several research reports. Needham & Company LLC lowered their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Barclays decreased their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Morgan Stanley reaffirmed an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 6th.

TScan Therapeutics Trading Up 2.6 %

Shares of NASDAQ TCRX traded up $0.04 during trading on Friday, hitting $1.59. 605,804 shares of the company traded hands, compared to its average volume of 320,462. TScan Therapeutics has a 1 year low of $1.51 and a 1 year high of $9.69. The company has a 50-day moving average price of $2.23 and a 200-day moving average price of $3.80. The firm has a market capitalization of $89.98 million, a P/E ratio of -1.50 and a beta of 0.91. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $1.43 million. On average, equities analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in TScan Therapeutics in the 4th quarter valued at about $32,000. Prudential Financial Inc. purchased a new position in TScan Therapeutics in the 4th quarter valued at about $32,000. ProShare Advisors LLC purchased a new position in TScan Therapeutics in the 4th quarter valued at about $40,000. Wells Fargo & Company MN raised its stake in shares of TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of TScan Therapeutics in the 4th quarter valued at about $59,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.